Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Holly M. Horton"'
Autor:
Eugene A. Zhukovsky, John R. Desjarlais, Roland Repp, Patrick F. Joyce, Igor Vostiar, John O. Richards, Seung Y. Chu, Sher Karki, Matthias Peipp, Erik Pong, Matthew J. Bernett, Holly M. Horton
Supplementary Figure 1 from Potent In vitro and In vivo Activity of an Fc-Engineered Anti-CD19 Monoclonal Antibody against Lymphoma and Leukemia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2413da5ba7c94cdaf17aec8c62e5aace
https://doi.org/10.1158/0008-5472.22375889
https://doi.org/10.1158/0008-5472.22375889
Autor:
Eugene A. Zhukovsky, John R. Desjarlais, Roland Repp, Patrick F. Joyce, Igor Vostiar, John O. Richards, Seung Y. Chu, Sher Karki, Matthias Peipp, Erik Pong, Matthew J. Bernett, Holly M. Horton
Supplementary Figure 2 from Potent In vitro and In vivo Activity of an Fc-Engineered Anti-CD19 Monoclonal Antibody against Lymphoma and Leukemia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11125e1a698038f30d8ba2f8c030c832
https://doi.org/10.1158/0008-5472.22375886.v1
https://doi.org/10.1158/0008-5472.22375886.v1
Autor:
Eugene A. Zhukovsky, John R. Desjarlais, Roland Repp, Patrick F. Joyce, Igor Vostiar, John O. Richards, Seung Y. Chu, Sher Karki, Matthias Peipp, Erik Pong, Matthew J. Bernett, Holly M. Horton
Supplementary Figure Legends 1-3 from Potent In vitro and In vivo Activity of an Fc-Engineered Anti-CD19 Monoclonal Antibody against Lymphoma and Leukemia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c922c9b540c134dfce296948c2e7cc7
https://doi.org/10.1158/0008-5472.22375880
https://doi.org/10.1158/0008-5472.22375880
Autor:
Michelle Fleury, Amy Watt, Lindsay Webb, Holly M. Horton, Robert Tighe, Robert Hofmeister, Derrick McCarthy, Courtney Anderson, Jian Ding, Dario A. Gutierrez, Adam Zieba
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundAdoptive cell therapies have shown great promise in hematological malignancies but have yielded little progress in the context of solid tumors. We have developed T cell receptor fusion construct (TRuC®) T cells, which are equipped with an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::897958bbfe06b0bf7f8761465d89318b
https://doaj.org/article/d44cfb388e964e529dc5269efe101901
https://doaj.org/article/d44cfb388e964e529dc5269efe101901
Autor:
Tracy E. Garrett, Richard A. Morgan, Howard J. Latimer, Holly M. Horton, Stacie L. Seidel, Kevin Friedman, Christopher J. Horvath, John W. Evans
Publikováno v:
Human Gene Therapy. 29:585-601
B-cell maturation antigen (BCMA) expression has been proposed as a marker for the identification of malignant plasma cells in patients with multiple myeloma (MM). Nearly all MM tumor cells express BCMA, while normal tissue expression is restricted to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afa5251811ccd48e2d11edd085f465f3
https://doi.org/10.1089/hum.2018.001
https://doi.org/10.1089/hum.2018.001
Autor:
Robert Hofmeister, Robert Tighe, Jian Ding, Adam Zieba, Holly M. Horton, Dario A. Gutierrez, Troy D. Patterson, Lindsay Webb, Michelle Fleury
Publikováno v:
Journal for ImmunoTherapy of Cancer. 9:A214-A214
BackgroundAdoptive cell therapies have shown great promise in hematological malignancies. To realize the potential of T cell therapies in solid tumors, we have developed T cell receptor fusion construct (TRuC®) T cells, which are equipped with an en
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f8dfbb611a3cc18bb8178923c81038e3
https://doi.org/10.1136/jitc-2021-sitc2021.203
https://doi.org/10.1136/jitc-2021-sitc2021.203
Autor:
Dario A. Gutierrez, Zieba Adam, Jessica Gierut, Holly M. Horton, Amy Watt, Robert Tighe, Jason Lajoie, Erica Liu, Michael Lofgren, Derrick McCarthy, Philippe Kiefer-Kwon, Robert Hofmeister, Vania Kenanova, Jian Ding, Brett Schrand
Publikováno v:
Cancer Research. 81:1528-1528
Previously we have described the design and antitumor activity of T cell receptor fusion constructs (TRuC™) that tether an antibody-derived binder to one of the TCR subunits to achieve redirected T cell killing of tumor cells independent of HLA. Di
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::689c52853bd417411082fe64ad47c5a4
https://doi.org/10.1158/1538-7445.am2021-1528
https://doi.org/10.1158/1538-7445.am2021-1528
Autor:
Dario A. Gutierrez, Holly M. Horton, Troy Patterson, Robert Hofmeister, Julie Donaghey, Philippe Kieffer-Kwon, Jessica Gierut, Ryan Milione, Julio Gomez-Rodriguez, Robert Tighe, Tiffany Chan, Joshua Daniel
Publikováno v:
Cancer Research. 81:1514-1514
The natural T cell receptor (TCR) recognizes its cognate peptide antigen only when presented on human leukocyte antigen (HLA) molecules and requires HLA matching of α/β TCR-engineered T cells for cancer therapy. To bypass the need for HLA matching,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4e664fbf68111a1b18517d2556636978
https://doi.org/10.1158/1538-7445.am2021-1514
https://doi.org/10.1158/1538-7445.am2021-1514
Autor:
Wai-Hang Leung, Joel Gay, Unja Martin, Tracy E. Garrett, Holly M. Horton, Michael T. Certo, Bruce R. Blazar, Richard A. Morgan, Philip D. Gregory, Jordan Jarjour, Alexander Astrakhan
Publikováno v:
JCI insight. 5
Chimeric antigen receptor (CAR) T cell therapies have achieved promising outcomes in several cancers, however more challenging oncology indications may necessitate advanced antigen receptor designs and functions. Here we describe a bipartite receptor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cedc649bdff2af6633dae81cecbe75a5
https://pubmed.ncbi.nlm.nih.gov/31039141
https://pubmed.ncbi.nlm.nih.gov/31039141
Autor:
Julie Donaghey, Holly M. Horton, Robert Hofmeister, Philippe Kieffer-Kwon, Robert Tighe, Tiffany Chan, Troy Patterson, Dario A. Gutierrez, Daniel R. Getts
Publikováno v:
Cancer Research. 80:2190-2190
The T-Cell Receptor (TCR) can be functionally split into antigen recognition mediated by the TCRα/β heterodimer and signal transduction triggered by the CD3 complex comprising CD3ϵ/γ, CD3ϵ/δ and CD3ζ/ζ dimers. Unlike antibodies, the TCR recog
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7e94a89cd504ef5dac2aeefee73033fe
https://doi.org/10.1158/1538-7445.am2020-2190
https://doi.org/10.1158/1538-7445.am2020-2190